Compositions and methods for short interfering nucleic acid inhibition of Na
View Patent ↗The invention provides short interfering nucleic acids, either single-stranded or double-stranded, that cause RNAi-induced degradation of mRNA from the Na v 1.8 sodium channel gene; to pharmaceutical compositions comprising such short interfering nucleic acids; recombinant vectors comprising such short interfering nucleic acids; a method for inhibiting translation of an mRNA; a method for inhibiting expression of a polypeptide; a method for blocking the membrane potential in a cell; a method for blocking the sodium current in a cell; and a method for inhibiting chronic pain.
1. An isolated or recombinant short interfering nucleic acid comprising the nucleotide sequence of SEQ ID NO: 1, or an analogue thereof.
2. The isolated or recombinant short interfering nucleic acid of claim 1 comprising the nucleotide sequence of SEQ ID NO: 1.
3. The isolated or recombinant short interfering nucleic acid of claim 1 comprising the nucleotide sequence of an analogue of SEQ ID NO: 1.
4. The isolated or recombinant short interfering nucleic acid of claim 2 , further comprising a 3′ overhang.
5. The isolated or recombinant short interfering nucleic acid of claim 3 , further comprising a 3′ overhang.
6. A pharmaceutical composition comprising the short interfering nucleic acid of claim 1 , and a pharmaceutically acceptable carrier.
7. A pharmaceutical composition comprising the short interfering nucleic acid of claim 2 , and a pharmaceutically acceptable carrier.
8. The isolated or recombinant short interfering nucleic acid of claim 1 , further comprising a complementary nucleotide sequence thereto.
9. The complementary nucleotide sequence of claim 8 , further comprising a 3′ overhang.
10. A pharmaceutical composition comprising the short interfering nucleic acid and complementary nucleotide sequence of claim 8 , and a pharmaceutically acceptable carrier.
11. The isolated or recombinant short interfering nucleic acid of claim 8 , wherein said nucleotide sequence and said complementary nucleotide sequence hybridize to form a duplex.
12. The duplex of claim 11 , wherein said nucleotide sequence further comprises a 3′ overhang and said complementary nucleotide sequence further comprises a 3′ overhang.
13. A pharmaceutical composition comprising the duplex of claim 11 , and a pharmaceutically acceptable carrier.
14. A pharmaceutical composition comprising the duplex of claim 12 , and a pharmaceutically acceptable carrier.
15. A pharmaceutical composition comprising the short interfering nucleic acid and complementary nucleotide sequence of claim 9 , and a pharmaceutically acceptable carrier.
16. An isolated or recombinant short interfering nucleic acid comprising the nucleotide sequence of SEQ ID NO: 1 and a complementary nucleotide sequence thereto.
17. The complementary nucleotide sequence of claim 16 , further comprising a 3′ overhang.
18. A pharmaceutical composition comprising the short interfering nucleic acid and complementary nucleotide sequence of claim 16 , and a pharmaceutically acceptable carrier.
19. The isolated or recombinant short interfering nucleic acid of claim 16 , wherein said nucleotide sequence and said complementary nucleotide sequence hybridize to form a duplex.
20. The duplex of claim 19 , wherein said nucleotide sequence further comprises a 3′ overhang and said complementary nucleotide sequence further comprises a 3′ overhang.
21. A pharmaceutical composition comprising the duplex of claim 19 , and a pharmaceutically acceptable carrier.
22. A pharmaceutical composition comprising the duplex of claim 20 , and a pharmaceutically acceptable carrier.
23. A pharmaceutical composition comprising the duplex of claim 17 , and a pharmaceutically acceptable carrier.
24. A recombinant vector comprising the nucleotide sequence of claim 1 .
25. A recombinant vector comprising the nucleotide sequence of claim 2 .